Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomization
Tom G. Richardson, Genevieve M Leyden, Qin Wang…·Michael Vaclav Holmes
This study uses Mendelian randomization to compare the effects of lipid-modifying drug targets on CAD risk and blood metabolome traits across 115,082 UK Biobank participants.